NUVL
Source profileNuvalent
Precision oncology
Company profile
CIK1861560
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
Zidesamtinib
ROS1-positive NSCLC
RegistrationFDA PDUFA
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| NUVL Nuvalent | Potential regulatory action window FDA PDUFA | Zidesamtinib | Registration | Q4 2026 | quarter | upcoming |
SEC filings
No sample filings for this company.
Press releases
No sample press releases for this company.
ClinicalTrials.gov studies
No linked sample studies for this company.
Change history
No sample changes yet.